Université de Lorraine, Nancy, France.
CNRS, UMR, 7039 CRAN, Nancy, France.
BMC Cancer. 2019 Mar 28;19(1):277. doi: 10.1186/s12885-019-5447-1.
In clinical oncology, only a few applications have been developed using HPV as a personalized tumor marker, a lack most probably related to the limited information obtained by the classical Polymerase Chain Reaction (PCR) approach. To overcome this limitation, we have recently developed the capture-based Next-Generation Sequencing (NGS) "CaptHPV" assay, designed to provide an extensive and comprehensive molecular characterization of HPV DNA sequences associated with neoplasias, ie the sequence of the viral genome (245 genotypes), its physical state, viral load, integration site and genomic alterations at integration locus. These data correspond to highly specific tumor markers that can be used to improve diagnosis and patient's follow-up.
We report here a case that is a straightforward and practical illustration of the power of the CaptHPV method. A patient developed successively a carcinoma of the anal canal and of the tongue. The two tumors were squamous cell carcinoma, found associated with HPV16 using PCR. In order to document a possible metastasis to the tongue from the anal cancer, we performed CaptHPV analysis on the two tumors. The analysis of the anal carcinoma found 55 viral/human hybrid reads allowing the identification of the HPV16 DNA integration in the 4q25 chromosomal band locus with a 178,808 bp deletion in the cell genome. Molecular analysis of the tongue tumor disclosed 6110 reads of HPV16, with a viral pattern strictly identical to that of the anal tumor. A total of 131 hybrid reads between HPV16 and the cell genome were found, corresponding exactly to the same locus of integration of viral DNA at the 4q25 site. The 178,808 bp genomic deletion was also found in the lingual tumor. The exact identity of HPV insertional signatures in the two tumors, demonstrates unambiguously that the tongue tumor derived from the anal cancer whereas neither histological immunophenotyping nor classical viral analysis using PCR could allow a definitive diagnosis.
Our observation indicates that the establishment of a detailed cartography of HPV DNA sequences in a tumor specimen provides crucial information for the design of specific biomarkers that can be used for diagnostic, prognostic or predictive purposes.
在临床肿瘤学中,仅有少数应用采用 HPV 作为个性化肿瘤标志物,这主要可能与经典聚合酶链反应(PCR)方法获得的信息有限有关。为了克服这一限制,我们最近开发了基于捕获的下一代测序(NGS)“CaptHPV”检测方法,旨在提供与肿瘤相关的 HPV DNA 序列的广泛而全面的分子特征,即病毒基因组的序列(245 种基因型)、其物理状态、病毒载量、整合部位和整合部位的基因组改变。这些数据对应于高度特异性的肿瘤标志物,可用于改善诊断和患者的随访。
我们在此报告一例病例,该病例直观而实用地说明了 CaptHPV 方法的强大功能。患者先后发生肛门癌和舌癌。两种肿瘤均为鳞状细胞癌,使用 PCR 发现与 HPV16 相关。为了证明舌癌可能是肛门癌的转移,我们对两种肿瘤进行了 CaptHPV 分析。肛门癌的分析发现了 55 个病毒/人杂交读段,可确定 HPV16DNA 在细胞基因组中的 4q25 染色体带位整合,细胞基因组中存在 178808bp 的缺失。舌肿瘤的分子分析显示有 6110 个 HPV16 读段,其病毒模式与肛门肿瘤完全相同。发现 HPV16 与细胞基因组之间共有 131 个杂交读段,正好对应于病毒 DNA 在 4q25 位的相同整合位。在舌肿瘤中也发现了 178808bp 的基因组缺失。两个肿瘤中 HPV 插入特征的完全相同,明确证明了舌肿瘤源自肛门癌,而组织学免疫表型或使用 PCR 的经典病毒分析均无法做出明确诊断。
我们的观察表明,在肿瘤标本中建立 HPV DNA 序列的详细图谱为设计可用于诊断、预后或预测目的的特异性生物标志物提供了关键信息。